Format

Send to

Choose Destination
JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924.

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

Author information

1
Division of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco, California.
2
Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital, San Francisco, California.
3
Division of General Internal Medicine, Columbia University Medical Center, New York, New York.
4
Institute for Clinical and Economic Review, Boston, Massachusetts.
5
Department of Medicine, University of California, San Francisco.
PMID:
28829863
PMCID:
PMC5817484
DOI:
10.1001/jama.2017.9924
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center